Medicine and Dentistry
Vasculotropin
100%
Soft Tissue Sarcoma
100%
Chronic Kidney Disease
100%
Cancer
75%
Prevalence
72%
Leiomyosarcoma
69%
Pancreas Adenocarcinoma
56%
Immunohistochemistry
56%
Clinical Feature
54%
Primary Health Care
50%
Hypophysitis
50%
Hepatitis B Vaccination
50%
Lung Cancer
50%
Nodular Melanoma
50%
Hepatocellular Carcinoma
50%
Pancreas Carcinoma
50%
Immunoglobulin A Nephropathy
50%
Sarcoma
50%
Lung Calcification
50%
Hormone Substitution
50%
Hemodialysis
50%
Veterans Affairs
50%
Malignant Neoplasm
46%
Carcinosarcoma
45%
Malignant Fibrous Histiocytoma
40%
Trastuzumab
31%
Hepatitis B Antibody
30%
Neoplasm
29%
Pancreas Cancer
29%
Renal Tubular Acidosis
25%
Immune-Related Adverse Events
25%
Retrospective Study
23%
Recombinant Hepatitis B Vaccine
20%
Patient Counseling
16%
Diabetes Mellitus
16%
Adenocarcinoma
16%
Disease
16%
Biopsy
16%
Analysis of Variance
16%
Log Rank Test
16%
Intracellular Signaling
16%
Membrane Receptor
16%
Bosentan
16%
Coronary Risk
16%
Observational Study
16%
Cancer Mortality
16%
Clinical Predictor
16%
End of Life Care
16%
Renal Replacement Therapy
16%
Outpatient
16%
Keyphrases
Leiomyosarcoma
55%
Clinical Features
54%
Overexpression
50%
Predictive Value
50%
Bone Marrow Iron
50%
Hypophysitis
50%
Vascular Endothelial Growth Factor
50%
Lung Cancer
50%
Soft Tissue Sarcoma
50%
Metastatic Calcification
50%
Living Donor Evaluation
50%
CD117
50%
Hormone Replacement Therapy
50%
Pancreatic Adenocarcinoma
50%
Veterans Affairs
50%
Dialysis Facility
50%
Lessons Learned
50%
Single-center Experience
50%
Hospice
50%
Smoking History
30%
Renal Tubular Acidosis
25%
Acute Tumor Lysis Syndrome
25%
Nephrotoxic Effect
25%
HER Family
25%
Renal Adverse Effects
25%
Vascular Endothelial Growth Factor Receptor Inhibitor
25%
Age at Diagnosis
25%
Immune-related Adverse Events
25%
Dermatofibrosarcoma
21%
Retrospective Observational Study
18%
Cancer Causes
17%
Cancer Mortality
17%
Hemodialysis Initiation
16%
Calcium Deposition
16%
Hemodialysis
16%
Vascular Endothelial Growth Factor Expression
15%
Malignant Fibrous Histiocytoma
15%
Histological Subtypes
15%
Statistical Analysis
12%
Clinical Predictors
12%
Survival Prediction
12%
Mortality Rate
12%
Type 1 Diabetes Mellitus (T1DM)
12%
Rank Analysis
12%
Incidence Rate
12%
Pre-dialysis Patients
12%
Protective Antibody Levels
12%
Early Chronic Kidney Disease
12%
Older Patients
12%
Biopsy-proven
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
75%
Malignant Neoplasm
73%
Nephrotoxicity
50%
Cetuximab
50%
Ipilimumab
50%
Hypophysitis
50%
Lung Cancer
50%
Proteinuria
50%
Aflibercept
50%
Monoclonal Antibody
50%
Rituximab
50%
Replacement Therapy
50%
Protein Tyrosine Kinase Inhibitor
50%
Acute Kidney Failure
50%
Electrolyte Disturbance
25%
Hypokalemia
25%
Hypomagnesemia
25%
Panitumumab
25%
Dasatinib
25%
Everolimus
25%
Kidney Tubule Acidosis
25%
Vasculotropin
25%
Mammalian Target of Rapamycin Inhibitor
25%
Side Effect
25%
Cytotoxic Agent
25%
Bevacizumab
25%
Epidermal Growth Factor Receptor
25%
Adverse Event
25%
Tumor Lysis Syndrome
25%
Vasculotropin Receptor
25%
Protein Tyrosine Kinase
25%
Gamma Urogastrone
25%
Kidney Disease
25%
Imatinib
25%
Coronary Risk
16%
Bosentan
16%
Overall Survival
9%
Kidney Infection
8%
Malignant Fibrous Histiocytoma
7%
Leiomyosarcoma
7%
Trastuzumab
6%
